Abingworth raises $375m life sciences fund, but medtech unlikely to get lion’s share
This article was originally published in Clinica
Executive Summary
International investment group Abingworth has closed its tenth life sciences fund worth £225m ($375m), which will be used to invest broadly across the life sciences industry in Europe and the US.